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Background Approximately 39% of the global diarrhoea deaths in children aged
5 years may be attributable to rotavirus infection. Two rotavirus
vaccines were recently introduced to the market, with evidence of
efficacy in the USA, Europe and Latin America. We sought to esti-
mate the effectiveness of these vaccines against rotavirus morbidity
and mortality.
Methods We conducted a systematic review of published efficacy and effec-
tiveness trials of rotavirus vaccines. Study descriptors and outcome
measures were abstracted into standardized tables and the quality
of each study was graded. We performed meta-analyses for any
outcome with two or more data points, and used child health epi-
demiology reference group (CHERG) Rules for Evidence Review to
estimate the effect of the vaccine on rotavirus mortality.
Results We identified six papers for abstraction, reporting results from four
studies. No studies reported diarrhoea or rotavirus deaths, but all
studies showed reductions in hospitalizations due to rotavirus or
diarrhoea of any aetiology, severe and any rotavirus infections
and diarrhoea episodes of any aetiology in children who received
rotavirus vaccine compared with placebo. Effectiveness against very
severe rotavirus infection best approximated effectiveness against
the fraction of diarrhoea deaths attributable to rotavirus, and was
estimated to be 74% (95% confidence interval: 35–90%).
Conclusions Rotavirus vaccines are efficacious against rotavirus morbidity and
mortality and have the potential to substantially reduce child mor-
tality in low-income countries if implemented appropriately.
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Background
Rotavirus is a leading cause of watery diarrhoea in
children, estimated to account for  39% of diarrhoea
hospitalizations in young children.
1 Applying this
fraction to the 1.7 million diarrhoea deaths among
children aged <5 years,
2 Parashar et al.
1 estimated
that rotavirus is responsible for 611000 diarrhoea
deaths annually. Rotavirus vaccines represent an
important preventive approach to reducing rotavirus
infections and, along with therapeutic interventions
such as oral rehydration solution and zinc supplemen-
tation, present an opportunity to decrease diarrhoea
morbidity and mortality.
Efforts to develop a rotavirus vaccine began in 1980s
and led in 1998 to the licensing and introduction of a
live attenuated rhesus rotavirus vaccine in the US
market. However, it was voluntarily withdrawn from
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i56the market in 1999 after reports of increased risk of
intussusception among vaccinated infants. Despite
this setback, development of other candidate rotavirus
vaccines continued. In 2006, two new oral rotavirus
vaccines were licensed and introduced in the USA
following large-scale safety and efficacy studies in
Europe and North and Latin America.
3,4 Studies are
ongoing in Asia and Africa to assess the safety and
efficacy of the vaccines in these populations.
In 2004, a Cochrane review of rotavirus vaccines
reported pooled efficacy estimates against severe rota-
virus ranging from 58% to 72%, depending on the
vaccine virus strain.
5 This review, however, included
efficacy data for any rotavirus vaccine, including the
withdrawn rhesus rotavirus vaccine and other vac-
cines never licensed or marketed.
5 Also, it did not
include Phase III efficacy data on the two currently
marketed rotavirus vaccines, as those efficacy trials
had not yet been completed. In recent years, numer-
ous reviews of the two new rotavirus vaccines have
been published.
6–17 To our knowledge, however, there
have been no systematic reviews or meta-analyses
assessing the effect of currently marketed vaccines
on severe rotavirus morbidity and mortality. Here,
we report the results of a systematic review and
meta-analyses assessing the estimated effect of rota-
virus vaccine on moderate to severe morbidity, which
we extrapolated to estimate the effect of the vaccine
on diarrhoea mortality attributable to rotavirus.
This review was prompted and shaped by the needs
of the computer-based Lives Saved Tool (LiST), which
combines effectiveness estimates for maternal, neona-
tal and child health (MNCH) interventions with
information about cause of death, coverage of inter-
ventions and population structure to estimate the
impact of different intervention packages and cover-
age levels on child mortality in selected geographic
areas over time. Evidence-based estimates of the
effectiveness of MNCH interventions against mortality
are a critical aspect of the LiST model. In that model,
an increase in coverage levels for an intervention
results in a reduction of deaths from one or more
causes, or in reduction of the prevalence of a risk
factor such as stunting. Therefore, the LiST reviews,
including this study, and the grading process used
were designed to provide estimates of the effect of
an intervention in reducing either a risk factor or a
death due to specific cause. For more details of the
review methods, the adapted GRADE approach, or the
LiST model, see other articles in this supplement.
Methods
According to child health epidemiology reference
group (CHERG) guidelines,
18 we searched published
literature from PubMed, the Cochrane Libraries and
all World Health Organization Regional Databases to
identify studies examining the effect of rotavirus vac-
cine on diarrhoea morbidity and mortality in children
aged <5 years. We used various combinations of rota-
virus vaccine, efficacy and effectiveness, and included pub-
lications of any language. We also contacted subject
matter experts to ascertain the status of ongoing effi-
cacy and effectiveness studies in Asia, Africa and
Latin America and included data from these studies
where full manuscripts and author permissions were
available.
Inclusion and exclusion criteria
We included Phase III efficacy trials and post-market
efficacy or effectiveness studies of currently marketed
rotavirus vaccines that reported one or more of the fol-
lowing outcomes in children aged <5 years: all-cause
mortality; diarrhoea- or rotavirus-specific mortality;
diarrhoea- or rotavirus-specific hospitalizations; or
incidence or risk of rotavirus or diarrhoeal disease.
Pre-clinical, Phase I and Phase II trials were excluded,
as were trials of vaccines were not marketed as
of January 2009. Thus, our review excluded trials of
the withdrawn rhesus rotavirus vaccine. The included
studies evaluated two vaccines: a pentavalent
human-bovine reassortant rotavirus vaccine and a
monovalent attenuated human rotavirus vaccine.
Abstraction and analysis
Studies meeting our inclusion/exclusion criteria were
categorized according to outcome, and key variables
from each were abstracted into standardized tables.
These variables were used to grade each study accord-
ing to the CHERG adaptation of the GRADE
technique.
18
In a separate standardized table, we summarized the
evidence by outcome and study design, including
study quality, generalizability and summary outcome
measures. For each outcome/study design category
with more than one study, we performed both fixed
and random effects meta-analyses and reported the
Mantel–Haenszel pooled relative risk and correspond-
ing 95% confidence interval (CI) or, if there was evi-
dence of heterogeneity, the DerSimonian–Laird pooled
relative risk and 95% CI. The meta-analyses of efficacy
trials included only efficacy estimates based on at
least 2 years or two rotavirus seasons of follow-up.
For efficacy trials that reported both intent-to-treat
and per protocol analyses, we used only the per pro-
tocol results in the meta-analysis, as this approach
allowed us to include the greatest number of studies.
However, we used the results of intent-to-treat ana-
lysis for the effectiveness data, as this approach pro-
vided a better measure of the potential impact of the
vaccine when implemented under routine conditions.
We did not perform a meta-analysis for the effective-
ness studies, as the settings and circulating rotavirus
strains were too different to assume a common
underlying effect. All analyses were performed using
STATA 10.1 statistical software.
19
ROTAVIRUS VACCINE FOR DIARRHOEA MORTALITY i57Results
We screened 410 titles and abstracts identified
through literature searches and contacts with subject
area experts. Of these, we reviewed 17 papers and
included seven in our final database (Figure 1). The
included three Phase III clinical trials, of which two
used the monovalent vaccine and one used the pen-
tavalent vaccine, and two case–control effectiveness
studies. The Phase III trials included European and
Latin American sites for both vaccines, as well as
US (including Navajo and Apache populations) and
Taiwanese sites for the pentavalent vaccine. The effec-
tiveness studies of the monovalent and pentavalent
vaccines were conducted in northern Australia and
Nicaragua, respectively. We identified studies report-
ing rotavirus hospitalizations (n¼5); diarrhoea hospi-
talizations (n¼4); severe rotavirus gastroenteritis
(n¼4); severe diarrhoea (n¼2); and rotavirus gastro-
enteritis of any severity (n¼2) (Supplementary
table 1). No studies reported any diarrhoea deaths.
Table 1 presents the summary characteristics
and meta-analysis results for each outcome.
The efficacy of the vaccine against serious rotavirus
morbidity in vaccinated infants, compared with
placebo, ranged from 89% (78–95%) for severe rota-
virus to 93% (77–98%) for rotavirus hospitalization.
The effectiveness of the pentavalent vaccine in Latin
America was somewhat reduced compared with the
efficacy estimates; the vaccine was 74% (35–90%)
effective against very severe rotavirus, 61% (38–75%)
effective against severe rotavirus, and 47% (22–64%)
effective against rotavirus hospitalizations. Similarly,
the monovalent vaccine was 57% (<0–83%) effective
against rotavirus hospitalizations in a predominantly
indigenous population in northern Australia.
20 In
accordance with the CHERG Rules, in the absence
of mortality data, we used effectiveness against seri-
ous morbidity, i.e. very severe rotavirus, which is
based on a clinical scoring system to ascertain the
most severe cases and those most likely to result in
death, to estimate the effect of rotavirus vaccine on
the fraction of diarrhoea mortality attributable to
rotavirus. Although this estimate comes from one
study, because it is an effectiveness study, it is
believed that it would more closely represent the
results that might be observed when rotavirus is
scaled up in a community setting. The estimated
1 paper reporting on 
1 case-control effectiveness study 
of pentavalent rotavirus vaccine
1 paper reporting on 
1 case-control effectiveness study 
of monovalent rotavirus vaccine
2 papers reporting 
on 1 Phase III RCT of
pentavalent rotavirus vaccine
3 papers reporting on 
2 Phase III/IIIb RCTs of 
monovalent rotavirus vaccine
7 eligible papers reporting
on rotavirus gastroenteritis in children under 5 years
Papers abstracted
7 papers identified for abstraction
8 Phase II studies excluded
2 studies excluded because study population 
included only premature or malnourished infants
17 papers reviewed
19 abstracts reviewed for eligibility
410 titles and abstracts identified in 
PubMed, Cochrane Library, and WHO Regional Databases 
391 titles excluded
Figure 1 Rotavirus search process
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ROTAVIRUS VACCINE FOR DIARRHOEA MORTALITY i59effect of the vaccine on rotavirus mortality in children
aged <5 years was thus 74% (35–90%) (Figure 1).
Discussion
Diarrhoeal diseases continue to kill  1.7 million chil-
dren aged <5 years annually,
2 despite the existence of
highly efficacious interventions for the treatment of
diarrhoea.
21–23 We estimated that currently marketed
rotavirus vaccines could prevent 74% (95% CI:
35–90%) of rotavirus deaths and 47–57% of rotavirus
hospitalizations (Figure 2).
We based our estimate on effectiveness rather than
efficacy data because this approach provides a better
measure of the potential impact of the vaccine on
rotavirus deaths when implemented under routine con-
ditions. We used very severe rotavirus rather than rota-
virus hospitalizations as a proxy for mortality because
hospitalizations include both severe and non-severe
cases, and rotavirus severity is based on a well-defined
scale that can be applied consistently across settings,
whereas rotavirus hospitalization rates may vary
according to local clinical guidelines. However, because
effectiveness against severe rotavirus has been reported
only for pentavalent vaccine in Nicaragua, the general-
izability of this estimate is limited.
Evidence suggests that rotavirus vaccine efficacy
may vary by setting, due to regional differences in
circulating rotavirus vaccine strains,
24 and reduced
efficacy of oral vaccines in settings with a high prev-
alence of malnutrition and gastrointestinal infec-
tions.
25,26 Additional efficacy trials of both vaccines
are underway in low-income African and Asian set-
tings where malnutrition and gastrointestinal infec-
tions are highly prevalent. Preliminary efficacy data
from Phase III trials of the monovalent rotavirus vac-
cine in Malawi and South Africa support some regio-
nal differences in vaccine efficacy, showing 77%
vaccine efficacy against severe rotavirus infection in
South Africa and 50% in Malawi.
27 These estimates
are somewhat lower than those seen in earlier trials
of monovalent vaccine in developed countries and
Latin America.
27 Peter et al.
27 have suggested that
rotavirus vaccine efficacy data may be extrapolated
to settings with similar under-five mortality rates.
Given much higher under-five mortality rates in
most sub-Saharan and South Asian countries com-
pared with the middle- and high-income settings in
which the earlier studies were conducted, it may not
be appropriate to apply our estimated mortality effect
to these regions; separate analyses and estimates will
be conducted for these high-mortality populations
when the complete results are published.
Our estimated effect size for rotavirus deaths is
based on effectiveness data for the pentavalent rota-
virus vaccine only. The monovalent and pentavalent
vaccines differ in important ways, including their ori-
gins and valencies, which could limit the generaliz-
ability of our effectiveness estimate to the monovalent
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the monovalent vaccine in El Salvador, however,
reported identical effectiveness against severe rota-
virus (74%),
28 suggesting that our effectiveness esti-
mate may be more broadly applicable to both vaccines
in this region.
Taken together, the effectiveness and efficacy data for
both rotavirus vaccines provide sufficient evidence to
conclude that rotavirus vaccines are highly efficacious
and effective in preventing severe rotavirus episodes
and rotavirus deaths in children aged <5 years in devel-
oped countries and Latin America. Rotavirus vaccines,
thus, have the potential to greatly reduce the fraction of
diarrhoea deaths attributable to rotavirus if high cover-
age levels are achieved for the recommended number
of doses. Although it would not be appropriate to sug-
gest that the effect size observed in Latin America mir-
rors what we can anticipate observing in Africa and
Asia, some countries may chose to use this estimate as
a proxy until regional specific data become available.
Additional data from efficacy trials in Asia and Africa,
further effectiveness studies and impact evaluations
for rotavirus vaccine introduction in Latin America
will be critical in strengthening the evidence base
for rotavirus vaccine, clarifying regional differences in
vaccine efficacy and confirming its effectiveness
globally.
Supplementary data
Supplementary data are available at IJE online.
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KEY MESSAGES
  Five large-scale high-quality studies provide evidence of the efficacy and effectiveness of rotavirus
vaccines against severe rotavirus infection and hospitalization.
  Rotavirus vaccines may prevent  74% of rotavirus deaths.
  Studies are underway in high-mortality, low-income countries to further validate this estimate in
these settings.
Severe Rotavirus (n=1; 1081 events)29
Rotavirus vaccine reduces severe rotavirus 
infections by 61% (38-75%)
Rule 5:  APPLY
Strong evidence of effectiveness against serious morbidity:  Highly plausible
Diarrhea & All-Cause Mortality (n=0) Rules 1, 2, 3 & 4: Do not apply
Rotavirus Hospitalizations (n=2; 1534 events)20,29 
Rotavirus vaccine reduces rotavirus 
hospitalizations by 47-57%
Possible Outcome Measures
Application of 
Standard Rules
Very Severe Rotavirus (n=1; 298 events)29
Rotavirus vaccine reduces very severe 
rotavirus infections by 74% (35-90%)
Figure 2 Application of standardized rules for choice of final outcome to estimate the effect of rotavirus vaccine on
rotavirus-specific mortality
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